Figure 4.

Immunogenicity evaluation of DNA prime-modified vaccinia Ankara (MVA) boost strategy. (a) Schematic of the vaccination regime; total four to five mice in each group. (b, c) Representative images of ELISpot and quantification of ELISpot SFUs in groups. (d, e) Percentage of proliferative CD4⁺ T (CD4⁺Ki67⁺) or proliferative CD8⁺ T (CD8⁺Ki67⁺) in splenocytes after stimulation with survivin or MUC1 protein. (f) Cytotoxicity evaluation of MVA vaccine-immunized mice (E: T, effector: target cells ratio). N.s., nonspecific protein; M: MUC1 protein; S, survivin protein. Groups drawn in colors: Vehicle (PBS; black), 3MVA (red), DNA-1 (brown), DNA-2 (pink), D/M (blue). One-way ANOVA followed by LSD analysis was performed to analyze the significant differences between groups. *P < .05; **P < .01; ***P < .001